Immunosenescence and hurdles in the clinical management of older HIV-patients. Issue 5 (4th July 2017)

• Record Type: Journal Article
• Authors: Ripa, Marco; Chiappetta, Stefania; Tambussi, Giuseppe
• Is Part Of: Virulence. Volume 8:Issue 5(2017)
• Page Start: 508
• Page End: 528
• Publication Date: 2017-07-04
• Subjects: AIDS -- comorbidities -- drug-drug interactions -- HIV -- immunosenescence; Virulence (Microbiology) -- Periodicals; Bacterial diseases -- Periodicals; Molecular microbiology -- Periodicals; 579.05
• DOI: 10.1080/21505594.2017.1292197
• Languages: English
• ISSNs: 2150-5608

Abstract

ABSTRACT: People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients.